Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-057335
Filing Date
2025-04-23
Accepted
2025-04-23 16:05:31
Documents
13

Document Format Files

Seq Description Document Type Size
1 DEFA14A phat-20250422.htm   iXBRL DEFA14A 19542
2 GRAPHIC img49164071_0.jpg GRAPHIC 307689
3 GRAPHIC img49164071_1.jpg GRAPHIC 216044
  Complete submission text file 0000950170-25-057335.txt   1427062

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT phat-20250422.xsd EX-101.SCH 7047
15 EXTRACTED XBRL INSTANCE DOCUMENT phat-20250422_htm.xml XML 1306
Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Filer) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39094 | Film No.: 25861404
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)